Kiora Pharma advances pipeline, initiates Phase 2 trials for retinal diseases.

• Kiora Pharmaceuticals reports Q2 2025 financial results • Advances pipeline with two active Phase 2 clinical trials for retinal diseases • Initiates KLARITY trial for KIO-104 in retinal inflammation • Strengthens market exclusivity for KIO-104 until 2043 • Enters option agreement for KIO-301 • Continues to progress pipeline of therapeutics for retinal diseases

Encinitas, California—(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced its second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. The company reported a net loss of $2.2 million for the second quarter of 2025, consistent with the net loss of $2.2 million in the second quarter of 2024. The company ended the quarter with $20.7 million in cash, cash equivalents, and short-term investments, along with $2.4 million in collaboration receivables and $0.7 million in research incentive tax credits [1].

Kiora's President and CEO, Brian M. Strem, Ph.D., highlighted the company's progress in advancing its Phase 2 clinical programs. The company initiated patient recruiting efforts for KIO-301, a molecular photoswitch for the treatment of inherited retinal diseases, and expanded its global commercialization network by entering a partnership with Senju. The KLARITY trial, assessing KIO-104 across several inflammatory retinal diseases, is actively recruiting patients [1].

The company also reported a significant increase in R&D expenses for the second quarter of 2025, totaling $2.6 million before recognizing $1.7 million in reimbursable expenses from Théa. This increase was mainly attributable to clinical trial activities. General and administrative expenses were $1.4 million for the second quarter of 2025, down from $1.5 million in the second quarter of 2024 [1].

Kiora Pharmaceuticals has granted a U.S. patent expanding the protection for KIO-104 for the treatment of ocular disease, further strengthening its market exclusivity until 2043. Additionally, the company entered an option agreement for KIO-301, which could potentially benefit the global population in need [1].

The company's anticipated runway remains into late 2027 based on existing cash reserves, beyond the anticipated readouts for ABACUS-2 and KLARITY. This timeframe could be extended further through the achievement of partnership milestones [1].

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. The company's pipeline includes KIO-104, a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment of retinal inflammation, and KIO-301, a molecular photoswitch for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease [1].

References:
[1] https://www.stocktitan.net/news/KPRX/kiora-pharmaceuticals-reports-second-quarter-2025-results-company-8eq7epvyz2q2.html
[2] https://seekingalpha.com/news/4482458-kiora-pharmaceuticals-gaap-eps-of-0_54